Skip to content

Study · Randomized controlled trial · n = 62 · 2014

7 results

Effects of PTH(1-84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial.

Sikjaer T, Rolighed L, Hess A, Fuglsang-Frederiksen A, Mosekilde L, Rejnmark L

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA1 Apr 2014Cited by 95 (Europe PMC)

PMID24687385 (opens in a new tab)DOI10.1007/s00198-014-2677-6 (opens in a new tab)PepBankPUB-24687385
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In hypoparathyroidism, PTH did not improve quality of life versus placebo.

    In plain wordsIn hypoparathyroidism, PTH did not improve quality of life versus placebo.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    No significant changeQuality of life
    Study

    n = 62

    Comparator
    Placebo
    Outcome group
    Quality of life · Whole body
    Studied dose
    100 μg/d · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Compared with placebo, PTH did not improve QoL or muscle function.
    1 context sentence
    Summary · context
    Sixty-two patients with chronic hypoPT were randomized to 6 months of treatment with either PTH(1-84) 100 μg/d s.c. or placebo, given as add-on therapy to conventional treatment.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In hypoparathyroidism, PTH did not improve muscle function versus placebo.

    In plain wordsIn hypoparathyroidism, PTH did not improve muscle function versus placebo.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    MixedMuscle function
    Study

    n = 62

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    100 μg/d · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Compared with placebo, PTH did not improve QoL or muscle function.
    1 context sentence
    Summary · context
    Sixty-two patients with chronic hypoPT were randomized to 6 months of treatment with either PTH(1-84) 100 μg/d s.c. or placebo, given as add-on therapy to conventional treatment.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In hypoparathyroidism, PTH decreased maximal elbow flexion force by 30% versus placebo.

    In plain wordsIn hypoparathyroidism, PTH decreased maximal elbow flexion force by 30% versus placebo.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    DecreaseElbow flexion maximal force
    Study

    n = 62

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    100 μg/d · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    Maximal force production change at elbow flexion
    30%
    PTH vs placebo, decrease

    Source sentences

    Summary
    Rather, max force production decreased significantly by 30 % at elbow flexion in the PTH group compared with the placebo group.
    1 context sentence
    Summary · context
    Sixty-two patients with chronic hypoPT were randomized to 6 months of treatment with either PTH(1-84) 100 μg/d s.c. or placebo, given as add-on therapy to conventional treatment.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In hypoparathyroidism, PTH showed a nonsignificant trend toward reduced upper extremity strength versus placebo.

    In plain wordsIn hypoparathyroidism, PTH showed a nonsignificant trend toward reduced arm strength versus placebo.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    DecreaseUpper extremity muscle strength
    Study

    n = 62

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    100 μg/d · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Moreover, there was a nonsignificant trend for muscle strength to decrease in the upper extremities and on knee extension in response to PTH.
    1 context sentence
    Summary · context
    Sixty-two patients with chronic hypoPT were randomized to 6 months of treatment with either PTH(1-84) 100 μg/d s.c. or placebo, given as add-on therapy to conventional treatment.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In hypoparathyroidism, PTH showed a nonsignificant trend toward reduced knee extension strength versus placebo.

    In plain wordsIn hypoparathyroidism, PTH showed a nonsignificant trend toward reduced knee extension strength versus placebo.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    DecreaseKnee extension muscle strength
    Study

    n = 62

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    100 μg/d · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Moreover, there was a nonsignificant trend for muscle strength to decrease in the upper extremities and on knee extension in response to PTH.
    1 context sentence
    Summary · context
    Sixty-two patients with chronic hypoPT were randomized to 6 months of treatment with either PTH(1-84) 100 μg/d s.c. or placebo, given as add-on therapy to conventional treatment.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In hypoparathyroidism, PTH did not affect postural stability versus placebo.

    In plain wordsIn hypoparathyroidism, PTH did not affect postural stability versus placebo.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    No significant changePostural stability
    Study

    n = 62

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    100 μg/d · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Treatment did not affect postural stability.
    1 context sentence
    Summary · context
    Sixty-two patients with chronic hypoPT were randomized to 6 months of treatment with either PTH(1-84) 100 μg/d s.c. or placebo, given as add-on therapy to conventional treatment.
  7. 07HumanNon-randomized trialEfficacy outcome

    In hypoparathyroidism, motor unit potential duration decreased slightly during PTH treatment, with no symptomatic myopathy.

    In plain wordsIn hypoparathyroidism, muscle electrical signal duration decreased slightly during PTH treatment, with no symptomatic myopathy.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    DecreaseMotor unit potential duration
    Study

    n: not reported in source

    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    100 μg/d · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Electromyography showed a slight decrease in the duration of motor unit potentials in the PTH group, indicating a tendency toward myopathy, which, however was not symptomatic.
    1 context sentence
    Summary · context
    Sixty-two patients with chronic hypoPT were randomized to 6 months of treatment with either PTH(1-84) 100 μg/d s.c. or placebo, given as add-on therapy to conventional treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT00730210

Treatment of Hypoparathyroidism With Subcutaneous PTH (1-84) Injections: Effects on Muscle Function and Quality of Life

University of Aarhusn = 62Jun 2008 to Aug 2010

Hypoparathyroidism

Trial pageClinicalTrials.govUpdated 24 Oct 2012

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.